EC Number   |
Inhibitors |
Structure |
|---|
    4.4.1.5 | (1E,4Z,6E)-4-(4-hydroxy-3-methoxybenzylidene)-1-(3-hydroxy-4-methoxyphenyl)-7-(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione |
three-ring curcumin derivative, in binding model two rings lay in the opening of the active site, the third is buried into hydrophobic pocket site |
   |
| 4.4.1.5 | (1E,6E)-4-(3,4-dimethoxybenzylidene)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione |
three-ring curcumin derivative, in binding model two rings lay in the opening of the active site, the third is buried into hydrophobic pocket site |
|
| 4.4.1.5 | (1E,6E)-4-(3-fluorobenzylidene)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione |
three-ring curcumin derivative, in binding model two rings lay in the opening of the active site, the third is buried into hydrophobic pocket site |
|
| 4.4.1.5 | (1E,6E)-4-(4-fluorobenzylidene)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione |
three-ring curcumin derivative, in binding model two rings lay in the opening of the active site, the third is buried into hydrophobic pocket site |
|
| 4.4.1.5 | (2S)-2-amino-3-[([(2R)-3-[(4-bromobenzyl)sulfanyl]-1-[(carboxymethyl)amino]-1-oxopropan-2-yl]carbamoyl)amino]propanoic acid |
- |
|
| 4.4.1.5 | (3Z)-3-(1,3-benzothiazol-2-yl)-4-(4-methoxyphenyl)but-3-enoic acid |
inhibitor based on binding mode of myricetin, contributuion of the Zn2+-chelating group to inhibitory activity |
|
| 4.4.1.5 | (S)-4-bromobenzyl glutathione |
potent Glx-I inhibitor |
|
| 4.4.1.5 | (S)-4-bromobenzylglutathione cyclopentyl diester |
competitive inhibitor of GLOI |
|
| 4.4.1.5 | (Z)-1-[N-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate |
decreases glyoxalase I expression and activity relative to untreated control cells, cells undergo apoptosis, apoptosis increases further on co-incubation with high glucose |
|
| 4.4.1.5 | 1'-hydroxy-6'-phenyl-3,4'-bipyridin-2'(1'H)-one |
- |
|
